Spartalizumab Versus Chemotherapy in Patients With Recurrent/Metastatic Nasopharyngeal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, Versus Chemotherapy in Patients With Recurrent/Metastatic Nasopharyngeal Cancer
Clin. Cancer Res 2021 Aug 25;[EPub Ahead of Print], C Even, HM Wang, SH Li, RK Ngan, A Dechaphunkul, L Zhang, CJ Yen, PC Chan, S Chakrabandhu, BBY Ma, S Tanasanvimon, VHF Lee, PJ Lou, Z Li, AI Spira, A Sukari, J Guigay, S McCune, J Gonzalez-Maffe, S Szpakowski, Y Yao, H Liang, J Mataraza, R Séchaud, L Manenti, DW LimFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.